JCM
BCLI

JS Capital Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

JS Capital Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-760
Closed -$52K – 145
2020
Q4 		$52K Buy
+760
New +$104K ﹤0.01% 136

Other funds holding BCLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

JS Capital Management's BCLI Position: Q1 2021 in Review

JS Capital Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2021, closing a stake of 760 shares — an estimated $52K sold.

JS Capital Management first reported a position in BCLI in Q4 2020 and held it in 1 quarter. The position peaked at $52K in Q4 2020. 75 funds tracked by Wall St. Rank hold BCLI as of Q1 2021.

  • JS Capital Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2021 after selling out during the quarter.
  • JS Capital Management sold 760 BRAINSTORM CELL THERAPUTC shares in Q1 2021, an estimated $52K.
  • JS Capital Management first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2020 and held it in 1 quarter.
  • JS Capital Management's BRAINSTORM CELL THERAPUTC position peaked at $52K in Q4 2020.
  • 75 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2021.

Based on JS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.